Pre-Market Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc. PR Newswire LONDON, September 25, 2013 LONDON, September 25, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Tuesday, September 24, 2013, the U.S. equity market ended on a mixed note. The S&P 500 and the Dow Jones Industrial Average fell by 0.26% and 0.43%, respectively, while the NASDAQ Composite gained 0.08%. Shares in the healthcare sector ended lower, even as the broader market fluctuated between gains and losses. The major movers in the industry included Dendreon Corporation (NASDAQ: DNDN), Stryker Corporation (NYSE: SYK), Novartis AG (NYSE: NVS), and Repros Therapeutics Inc. (NYSE: RPRX). AAAResearchReports.com initiated preliminary technical research on DNDN, SYK, NVS, and RPRX. These free reports are accessible by signing today at: http://www.aaaresearchreports.com/register/ Shares in Dendreon Corp. fell sharply on Tuesday, extending the losses from the previous trading session. The company's shares ended the day at $2.98, which is 1.81% lower than the previous day's price of $3.04. The company's shares vacillated between $2.97 and $3.07 during the trading session. A total of 2.44 million shares were traded, which is below the daily average volume of 4.51 million. Despite Tuesday's sharp decline, Dendreon Corp.'s stock has advanced 2.41% in the last one month, compared to a gain of 2.04% in the S&P 500 during the same period. Additionally, the company's shares are trading below their 50-day and 200-day moving averages of $3.64 and $4.66, respectively. The free technical analysis on DNDN is available by signing up at: http://www.AAAResearchReports.com/DNDN092513.pdf Stryker Corp.'s stock fell by 0.52% on Tuesday, even as the broader market ended on a mixed note. The company's shares closed the day at $70.83 after oscillating between $70.77 and $71.45. A total of 1.05 million shares were traded, which is below the daily average volume of 1.19 million. Despite Tuesday's pullback, the company's shares have advanced 3.72% in the last one month and 9.37% in the previous three months, outperforming the S&P 500 which has gained 2.04% and 7.90% during the respective periods. Further, Stryker Corp.'s stock is trading near its 52-week high of $71.94 as well as above its 50-day and 200-day moving averages of $69.97 and $65.21, respectively. Register now to download free research on SYK at: http://www.AAAResearchReports.com/SYK092513.pdf Shares in Novartis AG edged lower on Tuesday, reversing all of the gains from the previous trading session. The company's shares traded between $76.17 and $76.71 before finishing the day 0.48% lower at $76.37. A total of 0.71 million shares were traded, which is below the daily average volume of 1.39 million. Despite Tuesday's losses, the company's stock is up 1.26% in the last one month and 11.62% in the previous three months, compared to a gain of 2.04% and 7.90% in the S&P 500 during the respective periods. Moreover, Novartis AG's stock is trading near its 52-week high of $77.02 as well as above its 50-day and 200-day moving averages of $73.95 and $70.70, respectively. A free report on NVS can be accessed by registering at: http://www.AAAResearchReports.com/NVS092513.pdf On Tuesday, Repros Therapeutics Inc.'s stock fell sharply after hitting a new 52-week high of $29.79. The company's shares closed the day at $28.08, down 1.09% from the previous day's price of $28.39. A total of 0.94 million shares were traded, which is more than the daily average volume of 0.66 million. Despite Tuesday's sharp decline, Repros Therapeutics Inc.'s shares have rallied 49.04% in the last one month and 59.64% in the previous three months, outperforming the S&P 500 which has gained 2.04% and 7.90% during the respective periods. Furthermore, the company's stock is currently trading above its 50-day and 200-day moving averages of $21.13 and $16.86, respectively. Register with AAA Research Reports and download research on RPRX for free at: http://www.AAAResearchReports.com/RPRX092513.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: + 1 (646) 396-9126, Contact Name: Peter F. Jones Email ID: firstname.lastname@example.org
Pre-Market Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc.
Press spacebar to pause and continue. Press esc to stop.